Annexon, Inc. — Fiscal 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone fourth-quarter filing. Annexon is a clinical-stage biopharmaceutical company developing therapies that inhibit C1q and the classical complement pathway. It has no approved products and generated no product revenue.
Business Context and Development Status
- ANX005: Intravenous monoclonal antibody being developed for Guillain-Barré syndrome (GBS), Huntington’s disease, warm autoimmune hemolytic anemia and amyotrophic lateral sclerosis (ALS). Phase 2/3 GBS and Phase 2 Huntington’s disease trials were ongoing at year-end; Phase 2 trials in warm autoimmune hemolytic anemia and ALS were planned for 2021.
- ANX007: Intravitreal C1q Fab for ophthalmic diseases. A Phase 2 geographic atrophy trial was ongoing; the company expected data in 2023.
- ANX009: Subcutaneous C1q Fab in a first-in-human trial, intended for chronic autoimmune indications.
- Other programs: ANX105 and small-molecule classical-pathway modulators were expected to enter IND-enabling studies in 2021.
- ANX005 and ANX007 Phase 1b studies were described as well tolerated and showing full C1q and classical-pathway inhibition. The company cautioned that early clinical studies were not generally powered to establish efficacy.
Financial Performance and Liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue |
| Research and development expense | $49.3 million | $24.5 million | Up 101% |
| General and administrative expense | $14.2 million | $8.0 million | Up 78% |
| Total operating expenses | $63.5 million | $32.5 million | Up 95% |
| Net loss | $63.4 million | $37.2 million | Loss increased 71% |
| Net loss attributable to common stockholders | $70.3 million | $38.3 million | Loss increased |
| Basic and diluted loss per share | $4.15 | $88.30 | Not directly comparable due to 2020 IPO and share-count changes |
| Cash used in operating activities | $53.1 million | $28.4 million | Cash burn increased |
| Cash and cash equivalents | $268.6 million | $43.9 million | Increased substantially |
| Short-term investments | $82.6 million | None | New in 2020 |
The filing does not provide a meaningful operating margin because the company had no revenue. Operating loss was $63.5 million. There was no material debt outstanding at year-end. A $0.5 million Paycheck Protection Program loan obtained in April 2020 was repaid in full in May 2020.
Total cash, cash equivalents and short-term investments were approximately $351.2 million at December 31, 2020. Management expected existing capital resources to fund planned operating expenses and capital expenditures through 2023, although this estimate depends on clinical, regulatory, spending and financing assumptions. The financial statements state that cash on hand was sufficient to support operations for at least the following 12 months.
Cash Flow, Capitalization and Balance Sheet
- Financing activities generated $360.9 million in 2020, including approximately $262.4 million of net IPO proceeds and $96.8 million of net Series D preferred-stock proceeds.
- Investing cash outflow was $83.2 million, primarily due to $82.7 million of purchases of available-for-sale securities.
- Total assets were $355.9 million and total liabilities were $11.7 million at year-end.
- Stockholders’ equity was $344.3 million at year-end versus a deficit of $100.5 million at December 31, 2019, principally reflecting the IPO, preferred-stock conversion and related equity accounting.
- Common shares outstanding were 38,157,618 at December 31, 2020 and March 15, 2021.
Material Changes Versus 2019
- Research and development spending doubled as clinical programs advanced, clinical and nonclinical outside services expanded, contract manufacturing increased and headcount grew.
- General and administrative spending increased primarily from public-company readiness, accounting, legal, audit, insurance and personnel costs.
- The company completed its IPO in July 2020 and raised approximately $262.4 million net. All outstanding redeemable convertible preferred stock converted into common stock immediately before the IPO.
- The company completed a $102.0 million Series D preferred-stock financing before issuance costs; approximately $13.9 million of the proceeds came from related parties.
- The 2019 loss included a $5.7 million loss from remeasurement of a redeemable convertible preferred-stock liability. No comparable charge occurred in 2020.
- The company entered into a lease for approximately 65,818 square feet of office and laboratory space in Brisbane, California, expected to begin in November 2021 and run through October 2031. Future minimum operating lease payments totaled $52.9 million as of year-end 2020.
Guidance, Outlook and Management Commentary
- Management expected research and development and general and administrative expenses to increase substantially for the foreseeable future.
- The company expected to continue incurring losses and negative operating cash flow for at least several years and did not expect product revenue in the foreseeable future unless a candidate is approved and commercialized or a collaboration produces revenue.
- Management’s liquidity projection indicated funding through 2023, but the company expects to require additional financing. Future equity financing could dilute stockholders; debt financing could impose covenants and repayment obligations.
- COVID-19 was expected to cause potential delays or disruptions in patient enrollment, clinical-site operations, contract research, manufacturing, regulatory interactions and supply chains. The ultimate impact remained uncertain.
- The company completed no material legal proceedings at year-end. It disclosed potential obligations under its Stanford license, including annual fees, milestone payments and low-single-digit royalties on licensed-product sales.
Key Risks and Unusual Items
- The company is dependent on successful clinical development, regulatory approval and commercialization of early-stage product candidates, particularly ANX005 and ANX007.
- C1q inhibition is a novel therapeutic approach; early biomarker or target-engagement results may not translate into clinical efficacy or long-term safety.
- Clinical trials may be delayed, placed on hold, terminated or require additional studies. The GBS drug-drug interaction study with IVIg was designed for safety, pharmacokinetics and pharmacodynamics and was not powered to demonstrate efficacy.
- The company relies on third parties for clinical research, manufacturing, testing and supply. Manufacturing failures, quality issues, shortages or disruptions could delay development.
- COVID-19, patient-enrollment constraints, foreign-trial data acceptance, regulatory changes and competition from complement-directed or other therapies could impair programs.
- Intellectual-property protection is dependent partly on licensed rights, including Stanford patents. Patent challenges, license termination or infringement claims could materially affect commercialization prospects.
- The company had previously identified a material weakness in internal control over financial reporting and stated that it was remediated as of December 31, 2019. As an emerging growth company, it was exempt from an external auditor attestation report on internal control effectiveness.
- Federal and state net operating losses and tax credits were subject to valuation allowances and potential ownership-change limitations, which could restrict future utilization.
Facts Investors Should Verify
- Verify the current status, enrollment, endpoints and timelines for ANX005 GBS, Huntington’s disease, ALS and warm autoimmune hemolytic anemia trials.
- Verify whether ANX005 or ANX007 clinical results support efficacy beyond target engagement and biomarker changes, particularly in controlled trials.
- Reassess the cash runway against actual quarterly operating cash burn, planned trial expansion, manufacturing commitments and the Brisbane facility build-out.
- Review the need, timing and terms of future financing and the potential dilution from equity issuance, options and employee stock plans.
- Confirm regulatory interactions and the potential registration pathway for ANX005 in GBS, including whether additional pivotal trials may be required.
- Monitor COVID-19 and other enrollment, supply-chain, regulatory and foreign-trial risks.
- Review patent expiration dates, Stanford license obligations, ownership and enforceability of key patents, and any future intellectual-property disputes.